NCT02844582View on ClinicalTrials.gov

Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

December 20, 2017

Primary Completion Date

June 4, 2019

Study Completion Date

June 4, 2019

Conditions
Hormone-Resistant Prostate CancerStage IV Prostate Adenocarcinoma
Interventions
DRUG

Cabazitaxel

Given IV

DRUG

Prednisone

Given PO

Trial Locations (1)

95817

University of California Davis Comprehensive Cancer Center, Sacramento

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

University of California, Davis

OTHER